Key Highlights
- Eli Lilly reached an agreement to acquire Centessa Pharmaceuticals at $38 per share cash, representing roughly $6.3 billion in value
- An additional contingent value right (CVR) worth approximately $9 per share could bring the total transaction to $7.8 billion
- Centessa’s U.S. shares soared 46% during premarket hours following the announcement
- The deal focuses on acquiring Centessa’s sleep-wake disorder treatment portfolio
- Separately, Lilly revealed a $2.75 billion partnership with Insilico Medicine for AI-driven drug development
Eli Lilly revealed plans Tuesday to purchase Centessa Pharmaceuticals through a transaction worth approximately $6.3 billion. The pharmaceutical giant is offering $38 in cash for each share of the Frankfurt-based biotech company.
The acquisition structure includes a non-transferrable contingent value right valued at about $9 per share. Should this CVR be triggered, the complete transaction value would climb to roughly $7.8 billion.
Shares of Centessa traded in the United States jumped 46% before the opening bell after the deal was made public. The significant price increase demonstrates the substantial premium Lilly is offering to secure Centessa’s sleep disorder treatment assets.
Centessa Pharmaceuticals plc, CNTA
The transaction centers on treatments for sleep-wake disorders, representing a new therapeutic area for Lilly. Centessa offers a specialized development pipeline that Lilly believes has strong commercial potential.
This represents Lilly’s second blockbuster announcement in consecutive days. A day earlier, the pharmaceutical company unveiled a $2.75 billion collaboration with Insilico Medicine focused on commercializing AI-generated therapeutics worldwide.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s strategy of combining conventional pharmaceutical research with cutting-edge technological innovation.
Expanding Into Sleep Disorder Therapeutics
The Centessa purchase represents a deliberate strategic expansion into sleep-wake disorder medicines. This therapeutic segment has gained increasing momentum among leading pharmaceutical companies in recent years.
Centessa has focused on developing orexin receptor agonists, therapeutic compounds that stimulate the brain’s wakefulness pathways. These medications show considerable promise for addressing conditions including narcolepsy and chronic daytime drowsiness.
Lilly’s decision to offer a substantial premium indicates strong belief in the clinical value of these programs. The contingent value right mechanism ensures that portion of the compensation depends on achieving specific development objectives.
Artificial Intelligence Partnership Caps Active Period
The Insilico collaboration announced Monday introduces another strategic element to Lilly’s recent dealmaking. Insilico employs artificial intelligence to engineer novel drug molecules, an approach that may significantly reduce initial development timelines.
Lilly indicated it will license and advance therapeutic candidates identified through Insilico’s proprietary platform. Complete financial details beyond the headline $2.75 billion figure remain undisclosed.
Announcing two major transactions of this magnitude within a single day is remarkable even for a pharmaceutical company as large as Lilly. LLY shares traded approximately 1% higher Tuesday morning as the market absorbed both agreements.
Centessa’s Frankfurt-listed shares also experienced sharp gains following the news, as the cash proposal sits substantially above recent market prices.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
